On 5–6 November 2026, OPADE partners gathered at the Fondazione EBRIS in Salerno, Italy, for the project’s 3rd Annual Meeting, reviewing scientific and technical progress and addressing key strategic and operational matters during the General Assembly.
Nov 06, 2026.![]()
Salerno, Italy – The international consortium of OPADE (Optimise and Predict Antidepressant Efficacy for Patients with Major Depressive Disorders Using Multi-Omics Analysis and AI-Predictive Tool), funded by the European Commission’s Horizon Europe programme (Grant Agreement No. 101095436), successfully held its 3rd Annual Meeting on 5–6 November 2026.
Hosted by the Fondazione EBRIS, the meeting brought together clinical researchers, molecular biologists, data scientists and technology partners from across Europe and Latin America. The event, opened by Dr Giulio Corrivetti, Project Coordinator, provided an opportunity to assess overall project progress, exchange updates across work packages and align priorities for the final phase of the project.
Reviewing scientific and technical progress
The first day focused on reviewing progress across the project’s main research and innovation areas. Partners shared updates on the clinical observational study and patient assessment methodologies (WP1 and WP2), the development of multi-omics biomarkers and biobank activities (WP3), and the digital health and AI solutions, including the patient-support chatbot and the i-OPADE predictive tool (WP4). Discussions also covered communication, dissemination and exploitation activities (WP5), alongside dedicated sessions on ethics and the project’s Scientific Advisory Board (WP7 and SAB).
Strategic discussions and General Assembly
The second day combined parallel technical working sessions focusing on clinical and ethical aspects, multi-omics and AI, and exploitation and intellectual property rights (IPR).
These discussions were followed by the OPADE General Assembly, where partners addressed and formally approved key operational and strategic decisions to guide the consortium through the remaining project activities.
The meeting concluded with closing remarks from the OPADE coordination and presidency, reaffirming the partners’ shared commitment to advancing the project’s objectives and translating its research outcomes into new opportunities for more personalised approaches to the treatment of major depressive disorder.
The two days in Salerno provided an important opportunity to strengthen collaboration across the consortium, consolidate progress and prepare for the final stages of OPADE.


